Spots Global Cancer Trial Database for AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
Official Title: A Phase I, Open-label, Dose-escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients With Advanced Solid Malignancies
Study ID: NCT00704366
Conditions
Interventions
Study Description
Brief Summary: This is a dose escalation study to assess the safety and tolerability of AZD0530 in patients with advanced solid malignancies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Takatsuk, Osaka, Japan
Research Site, Sunto-gun, Shizuoka, Japan
Contact Details
Name: Mary Stuart, MD
Affiliation: AstraZeneca
Role: STUDY_CHAIR
Name: Narikazu Boku, MD
Affiliation: Saint Marianna University School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
